Zoetis (ZTS)
(Delayed Data from NYSE)
$169.56 USD
+0.12 (0.07%)
Updated May 31, 2024 04:00 PM ET
After-Market: $169.64 +0.08 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$169.56 USD
+0.12 (0.07%)
Updated May 31, 2024 04:00 PM ET
After-Market: $169.64 +0.08 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs
by Zacks Equity Research
Zoetis' (ZTS) leading animal health portfolio gets a boost with the approval of Simparica Trio.
ASRT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Small Drug Stock Outlook: Innovation Holds the Key to Growth
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Why Is Zoetis (ZTS) Up 5.5% Since Last Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
ASRT vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Procter & Gamble, T-Mobile, Zoetis, Autodesk and FedEx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, T-Mobile, Zoetis, Autodesk and FedEx
Top Stock Reports for Procter & Gamble, T-Mobile & Zoetis
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including Procter & Gamble (PG), T-Mobile (TMUS) and Zoetis (ZTS).
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Bayer Sells Animal Health Division to Elanco: Now What?
by Mitchell Moore
On Tuesday, Bayer (BAYRY) announced the sale of its animal-health division to American competitor Elanco (ELAN), for a net price of $7.6 billion. The deal is expected to close in mid-2020 after regulatory approval.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FTCS
HKMPF or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HKMPF vs. ZTS: Which Stock Is the Better Value Option?
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.
Has Zoetis (ZTS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zoetis (ZTS) Looks Good: Stock Adds 7.6% in Session
by Zacks Equity Research
Zoetis (ZTS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance
by Zacks Equity Research
Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.
Zoetis (ZTS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 9.76% and 2.07%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on top- and bottom-line numbers along with other pipeline updates, when Zoetis reports Q2 results.
CTLT vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
CTLT vs. ZTS: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: MarketAxess, Copart, WellCare Health, Zoetis and Intuit
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MarketAxess, Copart, WellCare Health, Zoetis and Intuit